Tatiana Schlossberg has publicly shared that she was diagnosed with acute myeloid leukemia (AML) , a rare and aggressive form of blood cancer, specifically with a mutation known as “inversion 3.”

What type of leukemia?

  • Multiple major news outlets report that Tatiana Schlossberg’s cancer is acute myeloid leukemia (AML), a cancer of the blood and bone marrow that affects myeloid cells.
  • Reports also note that her AML involves a rare genetic mutation called “inversion 3,” which is associated with a more aggressive disease course and higher risk of relapse.

How and when it was discovered

  • She was diagnosed in May 2024, shortly after giving birth to her second child, when doctors noticed an abnormally high white blood cell count following delivery.
  • What first looked like a possible pregnancy-related change was confirmed by further testing to be acute myeloid leukemia with this rare mutation.

Treatment journey so far

  • Schlossberg has undergone several rounds of intensive chemotherapy, two bone marrow (stem cell) transplants, and participation in multiple clinical trials, including advanced immunotherapy approaches.
  • Despite periods of remission, her leukemia has repeatedly returned, and her doctors have described the prognosis as terminal, estimating about a year to live as of late 2025.

What AML with inversion 3 means

  • Acute myeloid leukemia develops when the bone marrow produces large numbers of abnormal immature white blood cells (blasts) that crowd out healthy cells, leading to infection risk, bleeding, and fatigue.
  • The inversion 3 mutation is considered a high-risk subtype, meaning it often responds less durably to standard treatments and has a higher chance of relapse even after aggressive therapy.

Latest public context

  • Her essay in The New Yorker, published in November 2025, brought broad attention to AML and her specific high-risk subtype, as well as to the emotional impact on her young family and the wider Kennedy family.
  • Coverage across major outlets in late November 2025 emphasizes both the seriousness of her prognosis and the way her story has sparked renewed conversations about leukemia research and advanced treatments.

Information gathered from public forums or data available on the internet and portrayed here.